Detalhe da pesquisa
1.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
N Engl J Med
; 384(12): 1101-1112, 2021 03 25.
Artigo
Inglês
| MEDLINE | ID: mdl-33761207
2.
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Lancet
; 400(10348): 273-282, 2022 07 23.
Artigo
Inglês
| MEDLINE | ID: mdl-35871814
3.
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
J Am Acad Dermatol
; 86(1): 104-112, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34416294
4.
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet
; 396(10246): 255-266, 2020 07 25.
Artigo
Inglês
| MEDLINE | ID: mdl-32711801
5.
The age again in the eye of the COVID-19 storm: evidence-based decision making.
Immun Ageing
; 18(1): 24, 2021 May 20.
Artigo
Inglês
| MEDLINE | ID: mdl-34016150
6.
COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study.
Immun Ageing
; 17: 22, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32802142
7.
Abrocitinib for atopic dermatitis - Authors' reply.
Lancet
; 397(10270): 196, 2021 01 16.
Artigo
Inglês
| MEDLINE | ID: mdl-33453780
8.
Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
J Clin Rheumatol
; 23(4): 193-199, 2017 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-28145906
9.
Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose-response analysis.
J Pharmacokinet Pharmacodyn
; 43(3): 325-41, 2016 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27178257
10.
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
Am J Clin Dermatol
; 25(1): 127-138, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37624488
11.
Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial.
J Dermatolog Treat
; 34(1): 2200866, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37036183
12.
Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus - A proposal from an expert panel.
Autoimmun Rev
; 22(12): 103479, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37967782
13.
Laboratory and clinical practices in antinuclear antibody detection and related antigens: recommendations from a Spanish multicentre survey.
Immunol Res
; 71(5): 749-759, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37195550
14.
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary.
Immunotherapy
; 15(13): 975-980, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37254941
15.
Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
J Dermatolog Treat
; 33(5): 2605-2613, 2022 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-35763326
16.
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.
Immunotherapy
; 14(1): 5-14, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34775830
17.
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Am J Clin Dermatol
; 22(4): 541-554, 2021 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-33954933
18.
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
JAMA Dermatol
; 157(10): 1165-1173, 2021 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34406366
19.
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Am J Clin Dermatol
; 22(5): 693-707, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34406619
20.
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
JAMA Dermatol
; 156(8): 863-873, 2020 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32492087